The Scottish Medical Consortium (SMC) has accepted Ikervis for use for NHS patients in Scotland.
The ciclosporin eye drop treatment, manufactured by Japanese pharma company Santen, is indicated for the treatment of severe keratitis in adult patients with dry eye disease unresponsive to tear substitutes.
The SMC’s decision is based on results from a six-month phase III trial, with full advice available on the SMC’s website.
General manager for Santen in the UK and Ireland, Craig Wallace, said: “The acceptance of Ikervis by the SMC is great news for patients with severe keratitis.”
He added: “We’re proud to be the first manufacturer to provide licensed ciclosporin eye drops to patients in the UK.”